Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from ZYUS Life Sciences ( (TSE:ZYUS) ) is now available.
ZYUS Life Sciences has expanded its global intellectual property portfolio with the issuance of a European patent for its cannabinoid-based drug candidate, Trichomylin® softgel capsules, which are designed for pain management. This patent, validated in 22 European countries, is a significant milestone for ZYUS as it enhances global protection and supports the company’s strategy to address the unmet medical needs of chronic pain sufferers. Additionally, ZYUS announced a non-brokered private placement to raise up to $2 million, which will be used for general corporate and working capital purposes, further supporting its operational and strategic objectives.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a life sciences company dedicated to the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates, particularly for pain management. The company focuses on securing intellectual property protection and obtaining regulatory approval for non-opioid-based pharmaceutical solutions to create a transformational impact on patients’ lives.
YTD Price Performance: -18.68%
Average Trading Volume: 9,677
Technical Sentiment Signal: Buy
Current Market Cap: C$43.36M
Find detailed analytics on ZYUS stock on TipRanks’ Stock Analysis page.